Division of Hematology and Medical Oncology

Active Projects: 28

Project Investigator All Organizations Start date End date
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors Pamela Munster, MD Division of Hematology and Medical Oncology
Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumor Malignancies that have BRCA Mutations or Triple Negative Metastatic Breast Cancer Pamela Munster, MD Division of Hematology and Medical Oncology
A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer Pamela Munster, MD Division of Hematology and Medical Oncology
A Phase 1A/1B, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Pamela Munster, MD Division of Hematology and Medical Oncology
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma Division of Hematology and Medical Oncology
A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy Emily Bergsland, MD Division of Hematology and Medical Oncology
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel with or without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma Division of Hematology and Medical Oncology
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Solid Tumors Pamela Munster, MD Division of Hematology and Medical Oncology
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Advanced Non-small Cell Lung Carcinoma Division of Hematology and Medical Oncology
ADXS31-142 in Combination with Pembrolizumab (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer Division of Hematology and Medical Oncology
A Phase 1 Study to Evaluate the Effect of NKTR-102 for Injection (etirinotecan pegol) on the QT/QTc Interval in Patients With Advanced or Metastatic Solid Tumors Pamela Munster, MD Division of Hematology and Medical Oncology
A Phase 2 Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma (FLC) Division of Hematology and Medical Oncology
Mount Zion Health Fund - Harold Dobbs Cancer Research Fund Alan Venook, MD Division of Hematology and Medical Oncology
Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax®) in Combination with Doxorubicin HCl Liposomal (Doxil®) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-cell Lymphoma Ai Weiyun, MD, PhD Division of Hematology and Medical Oncology
Phase 1b Study of SAR650984 in Combo with Lenalidomide and Dexa for Treatment of Relapsed or Refractory Multiple Myeloma Thomas Martin, MD Division of Hematology and Medical Oncology
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer Katherine Van Loon Steitz, MD, MPH IGHS Faculty Affiliate, Division of Hematology and Medical Oncology
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® with Docetaxel in Patients with Bone Metastases From Castration Resistant Prostate Cancer Charles Ryan, MD Division of Hematology and Medical Oncology
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer Division of Hematology and Medical Oncology
Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies Pamela Munster, MD Division of Hematology and Medical Oncology
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma Jeffrey Wolf, MD Division of Hematology and Medical Oncology
An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men with Localized Prostate Cancer Undergoing Radical Prostatectomy Division of Hematology and Medical Oncology
Phase II Single Agent Study of Selinexor (KPT-330) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy with Abiraterone Charles Ryan, MD Division of Hematology and Medical Oncology
CC# 159518 A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer Pamela Munster, MD Division of Hematology and Medical Oncology
Phase III Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy vs Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Locally Advanced or Metastatic Non Small-Cell Lung Cancer Division of Hematology and Medical Oncology
Phase 1 Open Label, Multi-center Study to Assess the Safety, tolerability and Pharmacokinetics of Orally administered CUDC-907, an HDAC and PI3K Inhibitor in Subjects with Advanced/ Relapsed Solid Tumors Pamela Munster, MD Division of Hematology and Medical Oncology
CC# 16552 A Phase Ib, Open-Label Study Of The Safety And Tolerability Of Atezolizumab In Combination With Radium-223 Dichloride In Patients With Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment With An Androgen Pathway Inhib Division of Hematology and Medical Oncology
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer Pamela Munster, MD Division of Hematology and Medical Oncology
Multiple Myeloma Research Foundation Tissue Banking Agreement Thomas Martin, MD Division of Hematology and Medical Oncology

Archived Projects: 87

Project Investigator All Organizations Start date End date
Identification of the CD8+Cell Anti-HIV Factor (CAF) Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
JCF/Hellman Grant Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
JCF/Bransten Grant Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Role of Innate Immunity in Controlling HIV Infection Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
UCSF AIDS Research Training Program Jay Levy, MD Division of Hematology and Medical Oncology
Immunologic and Virologic Features of Early HIV Infection Jay Levy, MD Division of Hematology and Medical Oncology
Role of Innate Immunity in Controlling HIV Infection Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Molecular Epidemiology of the Human Immunodeficiency Virus in Mexico Jay Levy, MD Division of Hematology and Medical Oncology
Role of Innate Immunity in Controlling HIV Infection Jay Levy, MD Division of Hematology and Medical Oncology
Subcontract from UFL Prime: HIV/FIV-Cat-Model: A model to identify vaccine epitopes Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Identification of the CD8+ Cell Antiviral Factor (CAF) Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Role of Innate Immunity in Controlling HIV Infection Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Innate Immunity and Autophagy in Elite Controllers Division of Hematology and Medical Oncology
Chinese Fellowship Jay Levy, MD Division of Hematology and Medical Oncology
Identification of the CD8+ Cell Anti-HIV Factor (CAF) Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Protection from HIV Infection in Intravenous Drug Users Jay Levy, MD Division of Hematology and Medical Oncology
Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer Division of Hematology and Medical Oncology
HIV cure with CCR5 (-) human IPS hematopoietic stem cells Jay Levy, MD Division of Hematology and Medical Oncology
Compassionate Use of Marqibo for the Treatment of Refractory T-Cell Acute Lymphoblastic Leukemia Lawrence Kaplan, MD Division of Hematology and Medical Oncology
Sanofi-Aventis SAR650894 Program - Clinical Component Thomas Martin, MD Division of Hematology and Medical Oncology
Sanofi-Aventis SAR650894 Program - Research Component Thomas Martin, MD Division of Hematology and Medical Oncology
Individually Optimized Conditioning Using PK-directed Dose Adjustment of Once Daily IV Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant Ai Weiyun, MD, PhD Division of Hematology and Medical Oncology
Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK) in Patients with Advanced Cancer Pamela Munster, MD Division of Hematology and Medical Oncology
Phase 1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, A Humanized 1gG1 Antibody in Combination with Bevacizumab with or without Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors Pamela Munster, MD Division of Hematology and Medical Oncology
A Phase I Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients with Advanced Solid Tumors Pamela Munster, MD Division of Hematology and Medical Oncology
Chronic Effects of Chemotherapy on Brain Function Division of Hematology and Medical Oncology
BEACON Study (BrEAst Cancer Outcomes with NKTR-102): Phase 3 Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with Anthracycline, a Taxane and Capecitabine Division of Hematology and Medical Oncology
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma Pamela Munster, MD Division of Hematology and Medical Oncology
Research Fellowship Grant Alan Venook, MD Division of Hematology and Medical Oncology
A Phase 1B, Multi-Center, Open Label, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors Pamela Munster, MD Division of Hematology and Medical Oncology
A Pilot Study of FOLFOX in Combination with Bevacizumab in Patients with Advanced Neuroendocrine Tumors Emily Bergsland, MD Division of Hematology and Medical Oncology
Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Malignancies That Are Refractory to All Standard Pamela Munster, MD Division of Hematology and Medical Oncology
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available Division of Hematology and Medical Oncology
A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Pamela Munster, MD Division of Hematology and Medical Oncology
AIDS Malignancies Consortium Lawrence Kaplan, MD Division of Hematology and Medical Oncology
Identification of the CD8 Cell Anti-HIV Factor (CAF) Jay Levy, MD Division of Hematology and Medical Oncology
Support for a Multiple Myeloma Project Coordinator Jeffrey Wolf, MD Division of Hematology and Medical Oncology
Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Division of Hematology and Medical Oncology
Targeting Adaptive Pathways in Resistant CRPC Eric Small, MD Division of Hematology and Medical Oncology
Phase I Study of INC280 plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer. Division of Hematology and Medical Oncology
A Multicenter Phase I/II Trial of Abiraterone + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer Charles Ryan, MD Division of Hematology and Medical Oncology
A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer Charles Ryan, MD Division of Hematology and Medical Oncology
Patient Centered Videos to Enhance Informed Consent for Palliative Chemotherapy Katherine Van Loon Steitz, MD, MPH IGHS Faculty Affiliate, Division of Hematology and Medical Oncology
Beacon (Breast Cancer Outcomes with Nktr-102): a Phase 3 Study of Nktr-102 Versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline, Taxane and Capecitabine Division of Hematology and Medical Oncology
A Phase II, Single Arm Study of the Use of Steroid-Based Mouthwash to Prevent Stomatitis in Postmenopausal Women with Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated with Everolimus plus Exemestane. Division of Hematology and Medical Oncology
Cellular mechanisms of resistance to chemotherapy and the impact of immune modulating therapy, and molecular characterization of circulating tumor cells (CTCs) in patients with advanced breast cancer (ABC) Division of Hematology and Medical Oncology
Genetic Determinants of Capecitabine Toxicity Division of Hematology and Medical Oncology
Master Member Agreement: Translational Breast Cancer Research Consortium Division of Hematology and Medical Oncology
The Breast Cancer Clinical Trials Consortium Division of Hematology and Medical Oncology
Effect of an embedded palliative care program on the unmet needs of patients with metastatic breast cancer. Melanie Majure, MD Division of Hematology and Medical Oncology
The role of HDAC2 in hormone therapy resistance Pamela Munster, MD Division of Hematology and Medical Oncology
Enhancing the Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages Division of Hematology and Medical Oncology
Evaluation of Pomalidomide in Combination with High Dose Dexamethasone and Oral Cyclophosphamide in Patients with Relapsed and Refractory Myeloma Thomas Martin, MD Division of Hematology and Medical Oncology
Phase II study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer Division of Hematology and Medical Oncology
Dar es Salaam ESCC Case-Control Study Katherine Van Loon Steitz, MD, MPH Division of Hematology and Medical Oncology
Prostate Cancer Therapeutic Clinical Investigation "First in Man" Eric Small, MD Division of Hematology and Medical Oncology
Identification of the SNPs and their Interaction with environmental factors in Esophageal Cancer in Tanzania Li Zhang, PhD Division of Hematology and Medical Oncology
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer Charles Ryan, MD Division of Hematology and Medical Oncology
An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 in Patients Previously Treated with T-DM1 in a Genentech-Sponsored T-DM1 Study Division of Hematology and Medical Oncology
Serum Androgens as Predictors of Survival in Metastatic Prostate Cancer Charles Ryan, MD Division of Hematology and Medical Oncology
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer Pamela Munster, MD Division of Hematology and Medical Oncology
HIV cure with CCR5 negative human IPS hematopoietic stem cells Jay Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
A Phase 2 Pilot Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. Division of Hematology and Medical Oncology
CC#14952: Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors Division of Hematology and Medical Oncology
The PROMOTE Program: Precision Oncology and Molecular Targeting in Advanced Prostate Cancer Advancing the Promise of the PCF/SU2C/AACR West Coast Prostate Cancer Dream Team Eric Small, MD Division of Hematology and Medical Oncology
CARAVAN: Checkpoint-Radiation-Vaccine Neoadjuvant Trial for Metastatic Prostate Cancer Division of Hematology and Medical Oncology, Helen Diller Family Comprehensive Cancer Center
Real-World Treatment Patterns and Associated Outcomes Among Patients with Advanced Progressive Pancreatic Neuroendocrine Tumors Emily Bergsland, MD Division of Hematology and Medical Oncology
The Breast Cancer Clinical Trials Consortium Division of Hematology and Medical Oncology
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma Division of Hematology and Medical Oncology
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment Eric Small, MD Division of Hematology and Medical Oncology
Phase III Study Evaluating Palbociclib (PD-0332991), a Cycline-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor-Positive, HER2-Normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy "Penelope" Division of Hematology and Medical Oncology
Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 6 - BGJ398 for patients with tumors with FGFR genetic alterations Jackie (Chia-Ching) Wang, MD Division of Hematology and Medical Oncology
A Phase II, Open Study of the Clinical Activity, Safety and Tolerability of Lapatinib in Combination with Bevacizumab in Subjects with Advanced or Metastatic ErbB-2-Overexpressing Breast Cancer Division of Hematology and Medical Oncology
The Prostate Cancer Clinical Trials Consortium: Clinical Research Site Application Charles Ryan, MD Division of Hematology and Medical Oncology
Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Alan Venook, MD Division of Hematology and Medical Oncology
Metastatic escape mechanisms in TKI resistant lung cancer Division of Hematology and Medical Oncology
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer Eric Small, MD Division of Hematology and Medical Oncology
A Phase I/II Study Evaluating Microwave Hyperthermia and Thermodox (Lyso-Thermosensitive Liposomal Doxorubicin) in Patients with Breast Cancer Recurrence at the Chest Wall (DIGNITY) Division of Hematology and Medical Oncology
Prostate Cancer Foundation Young Investigator Award Division of Hematology and Medical Oncology
A Randomized Phase 2 Trial of Immediate vs. Delayed Anti-Ctla4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer Immunotherapy Division of Hematology and Medical Oncology
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer Charles Ryan, MD Division of Hematology and Medical Oncology
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence Division of Hematology and Medical Oncology
An Open-label, Multi-center, Extension Study of NKTR 102 in Subjects Previously Enrolled in NKTR-102 Studies Pamela Munster, MD Division of Hematology and Medical Oncology
Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment Pamela Munster, MD Division of Hematology and Medical Oncology
Phase 3 study of PD-0332991 (Oral CDK4/6 inhibitor) plus Letrozole versus placebo plus Letrozole for postmenopausal women with ER (+), HER2 (-) breast cancer who have not received prior systemic anti cancer therapies Division of Hematology and Medical Oncology
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Division of Hematology and Medical Oncology
Characterization of a New Anti-HIV Immune Protein Jay Levy, MD Division of Hematology and Medical Oncology